ATC kod: D06BX01, G01AF01
En studie av metronidazol gel vid rosacea visade likartad effekt hos kvinnor och män.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical metronidazole have been found. No difference between men and women has been shown for transdermal absorption in general [1].
In an open-label community-based study (145 men, 437 women) investigating the responsiveness to twice-daily application of metronidazole topical gel 0.75% in subjects with rosacea, the efficacy in reducing lesion count and improving rosacea severity was equivalent in men and women [2]. A small study of patients with mild or moderate papulopustular rosacea (7 men, 25 women) showed that 8 weeks treatment with topical metronidazole or terbinafine yielded similar effect in men and women [3]. Rosacea is a common chronic facial skin disease in which women are approximately 2-3 times more likely than men to be affected [4].
No studies with a clinically relevant sex analysis regarding adverse effects of topical metronidazole have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Fler kvinnor än män hämtade ut kräm/gel innehållande metronidazol (ATC-kod D06BX01) på recept i Sverige år 2015, totalt 14 287 kvinnor och 7329 män. Det motsvarar 2,9 respektive 1,5 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70-79 år hos båda könen. I genomsnitt var kräm/gel innehållande metronidazol 2,4 gånger vanligare hos kvinnor [4].
Uppdaterat: 2020-08-28
Litteratursökningsdatum: 2017-01-17
Faktagranskat av: Mia von Euler
Godkänt av: Karin Schenck-Gustafsson